UK industry hits out at human tissue fee hike
This article was originally published in Clinica
The UK's leading associations for the medtech, IVDs, bioscience and pharma industries have joined forces to voice their "grave concern" at increases in licence fees related to the use of human tissue, which came into effect today.
You may also be interested in...
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.